Compare Nerdwallet Inc (NRDS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nerdwallet Inc vs Summit Therapeutics Inc — how do they compare? Nerdwallet Inc trades at $9.68 (market cap $625.17M), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 21.9× Nerdwallet Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nerdwallet Inc for 45 Days and Summit Therapeutics Inc for 16 Days on average.
| NRDS | SMMT | |
|---|---|---|
Market Cap | $625.17M | $13.71B |
Volume | 1,321,316 | 6,173,057 |
Sector | Media | Health |
52-Week High | $15.93 | $26.38 |
52-Week Low | $7.58 | $12.43 |
Typical Hold Time | 45 Days | 16 Days |
Enterprise Value | $539.47M | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.74, up 7.21% today, showing strong momentum despite a recent Q2 2026 earnings miss. The stock exhibits bullish technical signals with positive moving averages and strong institutional support. Fundamentally, the company demonstrates robust revenue growth from $539M in 2022 to $837M in 2025, with improving profitability margins. Recent news highlights the company's Financial Resilience Index publications and Wall Street's positive outlook.
The outlook remains positive with analyst consensus favoring Buy ratings (66.7%) and projecting 27.9% upside potential. Key opportunities include continued revenue growth and margin expansion, while risks involve organic search pressure in core products and macroeconomic sensitivity. The stock presents a compelling value proposition with attractive valuation multiples.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
